Pharmaceutical Products M&A Transactions

Ipsen to acquire Memo Therapeutics AG for up to €700M, gaining a Phase II antibody for BKPyV. Kurma Partners and Eurazeo Group are key stakeholders in this significant biotech deal.

Dr. Max, owned by Penta Investments, has acquired Farmacie Italiane for €300 million, significantly growing its Italian pharmacy network to 300 locations.

SteriMax strengthens its Canadian market presence by acquiring Andone Pharmaceuticals, enhancing its healthcare and medical device portfolio. Learn more.

Ipsen secures Kartos Therapeutics' navtemadlin in a deal up to $1.75B, enhancing its hemato-oncology pipeline with a promising myelofibrosis treatment.

Ipsen secures navtemadlin, a novel myelofibrosis therapy, in a deal valued up to $1.3 billion, targeting unmet needs in rare blood cancers.

Boundless Bio

Boundless Bio and Serapha Bio unite in a merger, raising $230 million to pioneer a gene editing therapy for Alpha-1 Antitrypsin Deficiency.

German firm Stada eyes Cooper Consumer Health in a potential €6 billion deal, signaling significant consolidation in the European healthcare market.

Tredence enhances its healthcare and life sciences analytics services by acquiring KMK Consulting, strengthening its position in a key growth market.

CVC Capital Partners may exit Cooper Consumer Health for €6 billion, as CapVest-backed Stada explores acquisition talks. Market consolidation heats up.

Honasa Consumer, Mamaearth's parent, invests ₹135 crore in Fluence Pharma, strengthening its position in India's growing nutraceuticals market.

Model N strengthens 340B and gross-to-net revenue management with Kalderos acquisition, offering enhanced compliance and revenue reconciliation for life sciences.

EBI strengthens its bone healing solutions by acquiring Xstim, integrating innovative wearable technology for spinal fusion and fracture repair. Learn more.

AbbVie nears $10.9 billion deal for Apogee Therapeutics, boosting its inflammatory disease pipeline with a long-acting drug candidate. Industry M&A heats up.

Biogen strengthens its immunology pipeline by acquiring RayThera for up to $1 billion, gaining access to promising small-molecule therapies for immune-mediated diseases.

Boots

Sycamore Partners eyes $10B sale of Boots, attracting Wittington Investments and Sigma Healthcare. A shift from IPO plans signals major UK retail M&A.